Abbott Laboratories (N:ABT)

Business Focus: Medical Equipment

Aug 14, 2019 09:00 am ET
Abbott and Intoximeters Partner to Keep Roads Safer by Bringing Together Industry-leading Technology for Drug and Alcohol Testing
ABBOTT PARK, Ill., Aug. 14, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) and Intoximeters today announced an agreement for Intoximeters to market Abbott's SoToxaTM Mobile Test System – a handheld oral fluid roadside testing solution that rapidly and reliably detects recent drug use – alongside Intoximeters' Alco-Sensor® brand breath alcohol-testing products. This agreement will aid law enforcement agencies in their efforts to reduce the rate of drugged driving, which has become a serious road safety issue.[2] ...
Jul 17, 2019 07:31 am ET
Abbott Reports Second-Quarter 2019 Results
ABBOTT PARK, Ill., July 17, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2019....
Jul 17, 2019 07:00 am ET
Abbott Laboratories to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 17, 2019 / Abbott Laboratories (NYSE: ABT) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 17, 2019 at 9:00 AM Eastern Time.
Jul 15, 2019 12:46 pm ET
Abbott Receives U.S. Approval of Next-Generation MitraClip®, Bringing New Enhancements to Abbott's Leading MitraClip Platform
ABBOTT PARK, Ill., July 15, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the company has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip™ heart valve repair device to treat mitral regurgitation. The latest approval for the fourth-generation MitraClip device, MitraClip G4, puts new enhancements into the hands of physicians across the U.S. by delivering an expanded range of clip sizes, an alternative leaflet grasping feature and facilitation of procedure assessment in real time to offer doctors further options when treating mitral valve dise...
Jul 11, 2019 09:00 am ET
Abbott Announces FDA Approval of the Alinity™ s System, the Latest Technology for Screening and Protecting the U.S. Blood and Plasma Supply
ABBOTT PARK, Ill., July 11, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) announced today U.S. Food and Drug Administration (FDA) approval for its new blood and plasma screening Alinity™ s System.  This new solution will bring the latest screening technology to U.S. blood and plasma centers. Alinity s is designed to screen blood and plasma more efficiently within a smaller space versus commercially available competitive systems. In a testing specialty that can require extensive hands-on time, the additional automation and flexibility of Alinity s will help blood and plasma centers improve producti...
May 21, 2019 10:45 am ET
TRILUMINATE Study Shows Treatment with Abbott's First-of-its-Kind Minimally Invasive Device Reduces Tricuspid Heart Valve Leaks
PARIS, May 21, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced positive late-breaking data from its TRILUMINATE study of the company's minimally invasive tricuspid valve repair system. Results at 30 days demonstrated that the investigational device is associated with a reduction of tricuspid regurgitation (TR) symptoms – caused by a leaky tricuspid heart valve – suggesting a possible treatment option for people suffering from this difficult-to-manage structural heart disease. Abbott's transcatheter tricuspid valve repair (TTVR) system builds on the continued advances of the company's...
May 16, 2019 08:00 am ET
New ZonePerfect® Keto is 100% #TrueKeto with the Proven Blend of Macros for Effective Results
ABBOTT PARK, Ill., May 16, 2019 /PRNewswire/ -- You don't need to follow #TransformationTuesday on Instagram or read the latest pop culture magazine to know that nearly half of Americans are trying to lose weight.1 The ketogenic or "keto" diet – a high fat, moderate protein and very low carbohydrate eating pattern – is proven to be an effective weight management plan when followed correctly,2 yet not all keto products on the market have the right ratio of macronutrients ("macros") to yield the best results. To address this need, Abbott (NYSE: ABT) is launching new ZonePerfect® Keto made with...
May 15, 2019 07:18 am ET
Nearly 9 out of 10 College Students with Student Debt Say It's Important to Find a Company That Offers Loan Relief
ABBOTT PARK, Ill., May 15, 2019 /PRNewswire/ -- Student loan debt – affecting 1 in 4 Americans and topping $1.5 trillion – is one of the most pressing concerns of students graduating college this spring. ...
May 14, 2019 09:00 am ET
Abbott Partners With NIH On BRAIN Initiative to Advance Research for Neurological Disorders
ABBOTT PARK, Ill., May 14, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has partnered with the National Institutes of Health (NIH) on the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative to accelerate advancements in neuroscience research.  As part of the agreement, Abbott will provide the company's neuromodulation technologies—including directional deep brain stimulation (DBS), spinal cord stimulation (SCS), and dorsal root ganglion (DRG) therapy—for research related to these NIH initiatives to explore their application for chronic pain and...
May 07, 2019 09:00 am ET
Abbott to Present at UBS Global Healthcare Conference
ABBOTT PARK, Ill., May 7, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the UBS Global Healthcare Conference on Tuesday, May 21, 2019. Brian Yoor, executive vice president of finance and chief financial officer, will present at 10 a.m. Central time....
May 06, 2019 09:00 am ET
Abbott Launches Next-generation Detection Technology in the U.S. and Europe, Offering a Smarter Approach to 24/7 Heart Monitoring for People with Irregular Heartbeats
ABBOTT PARK, Ill., May 6, 2019 /PRNewswire/ -- Abbott today announced the launch of a new, smarter heart monitor for better arrhythmia detection—positive news for people at risk for irregular heartbeats. Now with CE Mark in Europe and U.S. Food and Drug Administration (FDA) clearance, the next-generation Confirm Rx™ insertable cardiac monitor (ICM), a paperclip-sized implantable device, combines smartphone connectivity and continuous, remote monitoring to track unpredictable heart rhythm problems for fast and accurate diagnosis. ...
May 02, 2019 08:00 am ET
Abbott Receives WHO Prequalification Approval for Breakthrough HIV Point-of-Care Test
ABBOTT PARK, Ill., May 2, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that m-PIMA™ HIV-1/2 VL, the world's first point-of-care viral load diagnostic test, has received the World Health Organization's Prequalification approval (WHO PQ). The test received CE Mark in December 2018. ...
Apr 30, 2019 09:00 am ET
Abbott, the U.S. Department of Defense and TRACK-TBI Partner to Study Point-of-Care Blood Test for Concussions
ABBOTT PARK, Ill., April 30, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the next phase of partnership with the U.S. Department of Defense (DoD) and researchers from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Network, one of the largest traumatic brain injury (TBI) efforts of its kind. Together the groups will conduct a clinical trial to evaluate the effectiveness of Abbott's point-of-care blood test technology, which is under development to help clinicians assess brain injuries within minutes, using only a few drops of a patient's bloo...
Apr 29, 2019 05:33 am ET
New Study Finds Abbott Blood Test Can Help Predict Future Cardiac Events in Adults with No Known Heart Disease
ABBOTT PARK, Ill., April 29, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that a new study published in Circulation found its High Sensitive Troponin-I blood test could predict the chance of developing a cardiac event years before it occurs in people with no symptoms when added to current heart disease assessments.1 Using data from the Atherosclerosis Risk in Communities (ARIC) study, researchers suggest doctors could add the test to routine physical assessments in healthy middle-aged and older adults to better predict their chances of developing heart disease. ...
Apr 17, 2019 07:45 am ET
Abbott Reports First-Quarter 2019 Results
ABBOTT PARK, Ill., April 17, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2019....
Apr 11, 2019 03:16 pm ET
Abbott and the Abbott Fund Support Relief Efforts for Cyclone Idai
ABBOTT PARK, Ill., April 11, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) and its foundation, the Abbott Fund, are providing more than $500,000 in grants and healthcare products to support relief efforts for Cyclone Idai in Southeast Africa, including Mozambique, Malawi and Zimbabwe. ...
Mar 20, 2019 09:00 am ET
Abbott Hosts Conference Call for First-Quarter Earnings
ABBOTT PARK, Ill., March 20, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2019 financial results on Wednesday, April 17, 2019, before the market opens.  ...
Mar 19, 2019 08:00 am ET
Abbott Announces CE Mark for Alinity™ m Diagnostics System and Assays, the Latest in Molecular Technology, to Help Deliver Critical Test Results and Benefits to Patients
ABBOTT PARK, Ill., March 19, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) announced today CE Mark for its Alinity™ m diagnostics system and assays. This new technology will help keep up with the growing demand for infectious disease testing. Alinity m will provide unprecedented flexibility in molecular diagnostic testing, allowing more tests to be done in shorter timeframes, while reducing the space and number of instruments needed to conduct large amounts of tests. ...
Mar 17, 2019 11:45 am ET
New Data for Abbott's HeartMate 3™ Highlights Unparalleled Performance of Industry's Leading Heart Pump
NEW ORLEANS, March 17, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new late-breaking data from the MOMENTUM 3 study, the world's largest randomized controlled trial to assess outcomes in patients receiving a heart pump to treat advanced heart failure. In reviewing data across the complete 1,028 patient cohort, MOMENTUM 3 met its primary endpoint of event free survival while showcasing improved rates of overall survival, quality of life and a reduction in adverse events with the HeartMate 3™ left ventricular assist device (LVAD). ...
Mar 17, 2019 09:00 am ET
New Late-Breaking Analyses from Landmark COAPT™ Trial Show Benefits of Abbott's MitraClip™ Device
NEW ORLEANS, March 17, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced positive late-breaking data from two separate analyses of the COAPT™ Trial showing additional key benefits from treatment with MitraClip™ for heart failure patients with clinically significant secondary (or functional) mitral regurgitation (MR), or leaky heart valve. Both data sets were presented today at the American College of Cardiology's (ACC) 68th Annual Scientific Session. On Thursday, the U.S. Food and Drug Administration (FDA) approved a new, expanded indication for MitraClip to treat secondary mitral regu...
Mar 14, 2019 01:52 pm ET
Abbott Receives FDA Approval for Expanded Indication for MitraClip™ Device
ABBOTT PARK, Ill., March 14, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication to its leading MitraClip™ device used to repair a leaky mitral valve without open-heart surgery. Supported by the results of the landmark COAPT™ Trial, MitraClip is the first transcatheter mitral valve intervention therapy approved to treat select heart failure patients with clinically significant secondary, or functional, mitral regurgitation (MR).     ...
Mar 06, 2019 08:00 am ET
Late-Breaking Data Presentations at ACC 2019 Highlight Abbott's Leading Cardiovascular Portfolio
ABBOTT PARK, Ill., March 6, 2019 /PRNewswire/ -- Key medical devices across Abbott's (NYSE: ABT) cardiovascular portfolio will be highlighted in five late-breaking clinical trials at the American College of Cardiology's 68th Annual Scientific Session (ACC 2019) from March 16 – 18 in New Orleans. The late-breaking studies showcase the depth and breadth of the company's cardiovascular portfolio, providing new data on outcomes with the following products: the MitraClip™ system for transcatheter mitral valve repair, the HeartMate 3™ heart pump, the CardioMEMS™ HF System for proactive heart failu...
Mar 05, 2019 08:00 am ET
Abbott's Latest Diagnostics Technology, Alinity, Selected by Regional Medical Laboratory, Inc. to Deliver Benefits to Hospitals and Patients
ABBOTT PARK, Ill., March 5, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that Regional Medical Laboratory, Inc. (RML) will use the company's most advanced technology, Alinity ci-series, to conduct diagnostic testing for millions of patients. RML, part of the Ascension network, which is the largest non-profit health system in the U.S., performs diagnostics testing for more than 2.4 million patients through hospital systems in Texas, Wisconsin, Oklahoma, Kansas and Tennessee.    ...
Feb 27, 2019 07:55 am ET
Report: Developing Opportunities within Abbott Laboratories, American Express, Welbilt, Cinemark, Barnes Group, and Nevsun Resources — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Abbott Laboratories (NYSE:ABT), American Express Company (NYSE:AXP),...
Feb 25, 2019 08:00 am ET
Abbott to Present at Barclays Global Healthcare Conference
ABBOTT PARK, Ill., Feb. 25, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2019. Brian Yoor, executive vice president of finance and chief financial officer, will present at 1:05 p.m. Central time. ...
Feb 22, 2019 09:34 am ET
Abbott Declares 381st Consecutive Quarterly Dividend
ABBOTT PARK, Ill., Feb. 22, 2019 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share. ...
Feb 21, 2019 08:40 am ET
New Real-World Evidence Analysis of Nearly Half a Million FreeStyle® Libre System Users Shows Higher Rates of Scanning Improves Glucose Control
BERLIN, Feb. 21, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced data from three real-world evidence studies that provide a comprehensive look at the global use of the FreeStyle® Libre flash glucose monitoring system and its impact on health outcomes for people living with diabetes. The new real-world evidence analyses, which for the first time included data from the United States, highlighted key user benefits, including reduction in prolonged hypoglycemia and better glucose control when using both the glucose level and trend arrow during meal times.  The data was presented today at...
Feb 20, 2019 08:00 am ET
Abbott and Novo Nordisk Enter Partnership to Provide Integrated Digital Solution to People with Diabetes Using Insulin
ABBOTT PARK, Ill. and BAGSVÆRD, Denmark, Feb. 20, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLinkii mobile app and LibreViewiii cloud-based system). The partnership reflects both companies′ commitment to make diabetes management easier by connecting key technologies such as continuous glucose monitoring (CGM) and connected insulin pens....
Feb 20, 2019 07:00 am ET
Abbott Introduces the World's Most Sensitive Rapid Diagnostic Test, Determine™ HBsAg 2, to Accelerate Hepatitis B Care
ABBOTT PARK, Ill., Feb. 20, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received CE Mark for the world's most sensitive rapid diagnostic test for the detection of hepatitis B surface antigen, the Determine™ HBsAg 2 test for use with serum, plasma or whole blood.1,2,3 This highly sensitive, easy-to-use, rapid lateral flow test enables identification of those with the virus and facilitates linkage to care in every healthcare setting. ...
Jan 23, 2019 06:45 am ET
Abbott Reports 2018 Results and Issues Strong Forecast for 2019
ABBOTT PARK, Ill., Jan. 23, 2019 /PRNewswire/ --  Abbott today announced financial results for the fourth quarter and full year ended Dec. 31, 2018, and issued financial outlook for 2019. ...
Jan 21, 2019 08:00 am ET
Abbott Offers a New Option for Physicians Treating Patients with Atrial Fibrillation
ABBOTT PARK, Ill., Jan. 21, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, a new ablation catheter designed to help physicians accurately and effectively treat atrial fibrillation (AFib). The approval further expands Abbott's portfolio of cardiac ablation tools that integrate with the company's EnSite Precision™ cardiac mapping system to help physicians develop more precise images of the heart during cardiac ablation procedures....
Jan 17, 2019 08:00 am ET
Japanese Red Cross Society Selects Abbott Technology to Screen Country's Blood and Plasma Supply
ABBOTT PARK, Ill., Jan. 17, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it has been selected by the Japanese Red Cross Society (JRC) to partner in screening the country's blood donations. The 8-year contract is for the exclusive supply of serological instrumentation, tests and consumables used for blood and plasma screening. The JRC screens approximately 5 million blood donations each year, helping ensure a safe supply of products needed for blood transfusions and plasma therapies. Abbott's broad portfolio of products is used to screen more than 60 percent of the world's blo...
Jan 16, 2019 08:00 am ET
Abbott To Acquire Cephea Valve Technologies, Inc.
ABBOTT PARK, Ill., Jan. 16, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease. Financial terms were not disclosed. Abbott provided capital and secured an option to purchase Cephea in 2015....
Jan 14, 2019 08:00 am ET
FDA Approves World's First Device for Treatment of Premature Babies and Newborns with an Opening in Their Hearts (a Common Congenital Defect)
ABBOTT PARK, Ill., Jan. 14, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) approved the Amplatzer Piccolo™ Occluder, the world's first medical device that can be implanted in the tiniest babies (weighing as little as two pounds) using a minimally invasive procedure to treat patent ductus arteriosus, or PDA. The Amplatzer Piccolo, a device even smaller than a small pea, now offers hope to premature infants and newborns who need corrective treatment, and who may be non-responsive to medical management and high risk to undergo corrective surg...
Jan 11, 2019 07:00 am ET
Abbott and "Malaria No More" Work Together to End Malaria in Odisha, India
ABBOTT PARK, Ill., Jan. 11, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it is supporting a partnership between the government of the eastern Indian state of Odisha and Malaria No More, providing technology, expertise and funding support to advance efforts to end malaria in the state. ...
Dec 19, 2018 02:00 pm ET
Get Bubbly this New Year with Abbott's New Pedialyte® Sparkling Rush™ Powder Packs
ABBOTT PARK, Ill., Dec. 19, 2018 /PRNewswire/ -- Flavored sparkling water is currently a taste bud darling, and fans can now enjoy a new effervescent option: Pedialyte® Sparkling Rush™ powder packs. Abbott (NYSE: ABT) developed this rehydration solution just in time for the holidays, so you get the refreshing fizz you crave in a convenient packet, to easily upgrade your water on the go. ...
Dec 17, 2018 08:00 am ET
Abbott Hosts Conference Call for Fourth-Quarter Earnings
ABBOTT PARK, Ill., Dec. 17, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2018 financial results on Wednesday, Jan. 23, 2019, before the market opens.  ...
Dec 14, 2018 10:08 am ET
Abbott Raises Quarterly Dividend 14%, Increasing Payouts for 47 Straight Years
ABBOTT PARK, Ill., Dec. 14, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend to 32 cents per share, marking a 14 percent increase....
Dec 11, 2018 08:00 am ET
Abbott to Present at J.P. Morgan Healthcare Conference
ABBOTT PARK, Ill., Dec. 11, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2019. Brian Yoor, executive vice president of finance and Chief Financial Officer, will present at the conference at 11 a.m. Central time. ...
Nov 15, 2018 08:00 am ET
New Approvals Allow Chronic Pain Sufferers to Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant
ABBOTT PARK, Ill., Nov. 15, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the launch of the new DRG Invisible Trial System, which is approved by the U.S. Food and Drug Administration (FDA) and received CE Mark in Europe. People battling complex chronic pain conditions can now use the DRG Invisible Trial System to try Abbott's dorsal root ganglion (DRG) stimulation—a clinically proven, non-opioid treatment option for targeted chronic pain management. Patients who find adequate pain relief with DRG therapy can then have Abbott's Proclaim™ DRG system implanted, empowering them to mana...
Nov 14, 2018 08:00 am ET
Abbott Recommends Rejection of Below-Market Mini-Tender Offer by Baker Mills LLC
ABBOTT PARK, Ill., Nov. 14, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approximately 0.003 percent of the company's outstanding shares. Baker Mills' offer price of $57.00 per share in cash is approximately 22 percent lower than the $72.79 closing price of Abbott common shares on Nov. 9, 2018, the last closing price prior to commencement of the offer. ...
Oct 26, 2018 07:45 am ET
Consolidated Research: 2018 Summary Expectations for Kulicke and Soffa Industries, QUALCOMM, Net Element, AT&T, Abbott Laboratories, and The Kroger — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kulicke and Soffa Industries, Inc. (NASDAQ:KLIC), QUALCOMM Incorporated...
Oct 25, 2018 09:00 am ET
Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results
ABBOTT PARK, Ill., Oct. 25, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has cleared its next-generation Influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing1,2. These new assays enable the fastest-ever3 time to molecular influenza A & B and Strep A results at the point of care.4 Currently available on the ID NOW™ platform (formerly Alere i), both assays have been granted a Clinical Laboratory Improvement Amendments (CLIA) certificate of waiver.  ...
Oct 19, 2018 09:00 am ET
Abbott's HeartMate 3 Heart Pump Now FDA Approved for Advanced Heart Failure Patients Not Eligible for a Heart Transplant
ABBOTT PARK, Ill., Oct. 19, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the HeartMate 3™ Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living with advanced heart failure. With the approval, physicians can now offer the HeartMate 3 system to patients not eligible for a transplant who will live with their device for the rest of their lives....
Oct 17, 2018 12:44 pm ET
New Study Shows Abbott's Novel Diagnostic Test has the Potential to Demonstrate Gold Standard Accuracy and Speed, Which Could Help Rule Out Heart Attacks Earlier at the Point of Care
ABBOTT PARK, Ill., Oct. 17, 2018 /PRNewswire/ -- For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. New data, published online in JAMA Cardiology, found a new blood test under development that is done right at the patient's side in as little as 15 minutes could identify nearly three-fifths (56.7 percent) of people at low-risk of experiencing a heart attack, similar to the results of a High Sensitive Troponin-I blood test done in the laboratory setting.1 ...
Oct 17, 2018 07:45 am ET
Abbott Reports Third-Quarter 2018 Results
ABBOTT PARK, Ill., Oct. 17, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2018....
Oct 15, 2018 08:30 am ET
Abbott Names Robert B. Ford President, Chief Operating Officer
ABBOTT PARK, Ill., Oct. 15, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that Robert B. Ford has been named president and chief operating officer, effective immediately. Mr. Ford, a 22-year Abbott veteran, was most recently executive vice president of Medical Devices, Abbott's largest business....
Oct 04, 2018 08:00 am ET
iPhone App for Abbott's FreeStyle Libre Flash Glucose Monitoring System Makes Diabetes Management Easier and More Convenient for Canadians
- FreeStyle LibreLink 1,2 app enables FreeStyle Libre System users to monitor their glucose directly with their iPhone ...
Oct 01, 2018 08:00 am ET
Abbott′s FreeStyle® Libre 2, with Optional Real-Time Alarms, Secures CE Mark for Use in Europe
ABBOTT PARK, Ill., Oct. 1, 2018 /PRNewswire/ -- People living with diabetes in Europe will now have the choice to be alerted in real-time of hypoglycemia (low glucose levels1) or hyperglycemia (high glucose levels1) through the FreeStyle® Libre 2 system, a continuous glucose monitoring system (CGM). Abbott (NYSE: ABT) today announced that it has secured CE Mark (Conformité Européenne) for its FreeStyle Libre 2 system—the next generation of FreeStyle Libre, which safely and successfully replaces self-monitoring of blood glucose without the use of finger sticks2 and now offers optional glucose...
Sep 27, 2018 08:30 am ET
New Research Coverage Highlights CyberArk Software, Mercer International, American Airlines Group, Abbott Laboratories, Open Text, and The Kroger — Consolidated Revenues, Company Growth, and Expectati
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CyberArk Software Ltd. (NASDAQ:CYBR), Mercer International Inc....
Sep 26, 2018 06:01 pm ET
Abbott Receives CE Mark for First Troponin Test to Help Predict the Chance of Heart Attack in Apparently Healthy Adults Potentially Months to Years in Advance
ABBOTT PARK, Ill., Sept. 26, 2018 /PRNewswire/ -- Cardiovascular diseases are the leading cause of death globally.1 Yet unlike other conditions, heart disease can be prevented if identified early and managed through lifestyle changes and medication as needed.  To help people take control of their heart health, Abbott (NYSE: ABT) today announced that its High Sensitive Troponin-I blood test is the first troponin test with CE Mark that can more accurately predict the chances of having a heart attack or other cardiac event potentially months to years in advance in people who otherwise appear he...
Sep 25, 2018 02:45 pm ET
One-Year Results from Real-World Study Showed Abbott's Portico™ Transcatheter Aortic Valve Safely and Successfully Reduced Severe Aortic Stenosis
SAN DIEGO, Sept. 25, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced one-year results from a real-world, international, multicenter, 941-patient study of the company's Portico™ transcatheter aortic valve replacement (TAVR) system in patients with symptomatic, severe aortic stenosis – a life-threatening narrowing of the heart's aortic valve. At one year, implantation with the Portico valve was safe and associated with low rates of stroke, death and leaks between patients' natural heart tissue and the Portico valve.  ...
Sep 23, 2018 01:20 pm ET
Landmark Study Shows Treatment with Abbott's MitraClip® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation
SAN DIEGO, Sept. 23, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced positive clinical study results from a randomized controlled trial comparing treatment with the MitraClip® device to guideline-directed medical therapy in select patients with secondary (or functional) mitral regurgitation, or a leaky heart valve, as a result of advanced heart failure. The landmark COAPT study met both the primary safety and efficacy endpoints and all secondary endpoints, and showed treatment with MitraClip plus medical therapy was superior to medical therapy alone in reducing rates of heart failure...
Sep 19, 2018 09:00 am ET
Abbott Hosts Conference Call for Third-Quarter Earnings
ABBOTT PARK, Ill., Sept. 19, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2018 financial results on Wednesday, Oct. 17, 2018, before the market opens.  ...
Sep 13, 2018 11:14 am ET
Abbott Declares 379th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., Sept. 13, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 28 cents per share. ...
Sep 13, 2018 10:58 am ET
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
ABBOTT PARK, Ill., Sept. 13, 2018 /PRNewswire/ -- For the sixth consecutive year, Abbott (NYSE: ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability and responsibility. As the industry leader in Health Care Equipment & Supplies, Abbott is one of the 60 companies recognized for leading their respective global industries. ...
Sep 04, 2018 09:00 am ET
New Coverage Decision Extends Abbott's Innovative Pain Therapy Option to 22 Million Americans Living with Chronic Pain
ABBOTT PARK, Ill., Sept. 4, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new national coverage determination for the company's dorsal root ganglion (DRG) neurostimulation pain therapy through Aetna®, a leading health benefits company in the United States. With this coverage decision, Aetna will provide more than 22 million medical plan members with access to Abbott's DRG therapy for people with chronic pain. Aetna already covers Abbott's spinal cord stimulation therapies. Favorable coverage decisions for neurostimulation therapies by private payers such as Aetna support the goal...
Aug 02, 2018 09:00 am ET
Abbott Expands its Directional Deep Brain Stimulation Therapy by Offering New MR-Conditional Labeling
ABBOTT PARK, Ill., Aug. 2, 2018 /PRNewswire/ -- Parkinson's disease and essential tremor patients can now benefit from upgraded functionality with Abbott's Infinity™ DBS system. Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval for an over-the-air software upgrade for all currently implanted Infinity DBS systems that delivers magnetic resonance (MR)-conditional labeling and innovative features. This life-changing technology from Abbott helps patients with progressive diseases live better....
Jul 27, 2018 01:00 pm ET
Abbott's FreeStyle® Libre 14 Day Flash Glucose Monitoring System Now Approved in U.S.
ABBOTT PARK, Ill., July 27, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle® Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to 14 days with high accuracy. This approval makes Abbott's revolutionary continuous glucose monitor (CGM) the longest lasting self-applied personal glucose sensor available on the market. ...
Jul 26, 2018 09:00 am ET
Abbott Begins U.S. Pivotal Trial for the Tendyne Mitral Valve Replacement System to Treat Patients with Heart Valve Disease
ABBOTT PARK, Ill., July 26, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has initiated a pivotal clinical study in the U.S. of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system for the treatment of mitral regurgitation. The trial will evaluate the safety and efficacy of the treatment in patients suffering from mitral regurgitation (MR), known as a leaky heart valve. The investigational Tendyne device is the first and only mitral valve replacement that can be repositioned and fully retrieved, allowing the surgeon to precisely place the device during implantation, ...
Jul 24, 2018 04:30 pm ET
ViewRay Appoints Scott Drake as President, Chief Executive Officer and a Member of the Board of Directors, Shar Matin as Chief Operating Officer, and D. Keith Grossman as a Member of the Board of Dire
CLEVELAND, July 24, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the market-leading MRI-guided radiation therapy system, announced today the appointment of medical device industry veterans Scott Drake as its President and Chief Executive Officer and Shar Matin as its Chief Operating Officer, effective immediately.  In connection with his appointment, Mr. Drake has also been appointed to the ViewRay Board of Directors.  In addition, ViewRay announced the appointment of D. Keith Grossman to the ViewRay Board of Directors....
Jul 18, 2018 07:45 am ET
Abbott Reports Second-Quarter 2018 Results
ABBOTT PARK, Ill., July 18, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2018....
Jul 12, 2018 09:00 am ET
Abbott Receives FDA Approval for Next-Generation MitraClip® Device to Treat People with Leaky Heart Valves
- Innovations designed to allow doctors to treat more types of cases and anatomies ...
Jun 26, 2018 07:00 am ET
Abbott Announces Freedom 2 Save Program for Employees to Address Student Debt
ABBOTT PARK, Ill., June 26, 2018 /PRNewswire/ -- Historic levels of student debt have forced many people to choose between saving for their futures and paying off school loans. Abbott (NYSE: ABT) today announced a groundbreaking program that addresses the student debt crisis and changes that math.  ...
Jun 25, 2018 09:00 am ET
New Late-Breaking Data at ADA Underscore Significant Benefits of Abbott's FreeStyle Libre System for People Living with Diabetes
ORLANDO, Fla., June 25, 2018 /PRNewswire/ -- Abbott today announced results from multiple new clinical and real-world studies that provide a comprehensive look at the global use of the FreeStyle Libre system, the company's revolutionary continuous glucose monitor (CGM), and its impact on health outcomes across various patient populations and countries. These data were presented as part of multiple late-breaking abstracts at the American Diabetes Association (ADA) 78th Scientific Sessions in Orlando, Fla. ...
Jun 20, 2018 09:00 am ET
Abbott Hosts Conference Call for Second-Quarter Earnings
ABBOTT PARK, Ill., June 20, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2018 financial results on Wednesday, July 18, 2018, before the market opens.  ...
Jun 14, 2018 07:30 am ET
Report: Developing Opportunities within Abbott Laboratories, Markel, Microsoft, Gazit-Globe, National General, and ANGI Homeservices — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Abbott Laboratories (NYSE:ABT), Markel Corporation (NYSE:MKL), Microsoft...
Jun 08, 2018 10:15 am ET
Abbott Declares 378th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., June 8, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 28 cents per share....
May 31, 2018 08:00 am ET
Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management
ABBOTT PARK, Ill., May 31, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the launch of its Afinion™ 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 builds on Abbott's heritage in diabetes care by empowering patients with information about their health that they can discuss with their providers during a single visit. ...
May 23, 2018 09:00 am ET
Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease
ABBOTT PARK, Ill., May 23, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for XIENCE SierraTM, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent system. XIENCE stents are among the world's most-used and studied stents and have an exceptional safety record with low rates of complications. Design and technology advances in this generation of XIENCE include features specifically designed for the treatment of complex blockages that now account for up to 70 percent of cases.1...
May 23, 2018 06:00 am ET
Abbott's Investigational Tendyne™ Device for Mitral Valve Replacement Demonstrates Positive Outcomes at 30 Days in Global Study
PARIS, May 23, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system, the first and only mitral replacement valve that is repositionable and fully retrievable to allow for more precise implantation, helping improve patient outcomes. The trial is the largest study of a transcatheter mitral valve replacement device to date. Results at 30 days demonstrated that Tendyne is associated with a significant reduction of mitral regurgitation symptoms and low mo...
May 22, 2018 06:20 am ET
Five-Year Study Data Confirm Positive Outcomes for Patients When Abbott Diagnostic Tool Was Used to Guide Heart Stenting Decisions
PARIS, May 22, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced five-year results from the FAME 2 study, which showed that patients had fewer major adverse cardiac events (MACE) when they received a heart stent guided by Abbott's fractional flow reserve (FFR) diagnostic tool in combination with medical therapy compared to patients who received only medical therapy. MACE is defined as heart attack, death and urgent need to reestablish blood flow. Abbott's PressureWireTM uses the diagnostic metric FFR to measure the pressure of blood as it flows through a patient's blocked artery. This ...
May 03, 2018 09:00 am ET
Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter
ABBOTT PARK, Ill., May 3, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance of the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™. Advisor HD Grid employs a new design that allows physicians to see things differently, capturing and analyzing data in a novel manner to create highly detailed maps of the heart that better differentiate healthy from unhealthy tissue. The new mapping catheter builds upon Abbott's innovative products designed to improve how physicians perform cardiac ablation procedures, including the EnSite Precision Car...
May 02, 2018 09:00 am ET
Abbott's XIENCE Sierra™ Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease
ABBOTT PARK, Ill., May 2, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that Japan's Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent. XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases. ...
Apr 23, 2018 09:00 am ET
Sanquin Selects Abbott's "Alinity™ s" Solution for Blood and Plasma Screening
AMSTERDAM, April 23, 2018 /PRNewswire/ -- Sanquin and Abbott (NYSE: ABT) announced today that they signed a multiple-year contract for the supply of primary serological equipment and consumables, including Abbott's Alinity™ s system, for blood and plasma screening.i This agreement extends Abbott and Sanquin's long-standing relationship of more than 10 years. ...
Apr 20, 2018 10:10 am ET
Abbott Extends Title Sponsorship of Abbott World Marathon Majors through 2023
LONDON, April 20, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) and the World Marathon Majors today announced the renewal of Abbott's title sponsorship. The partnership will extend into 2023, with the new four-year agreement beginning in 2019. Abbott became the first title sponsor of the series in 2015....
Apr 18, 2018 09:31 am ET
Here's what you need to know about Abbott Laboratories, eBay, Southwest Airlines Co., Morgan Stanley and Riot Blockchain Inc.
CHICAGO, April 18, 2018 /PRNewswire/ -- InvestorsObserver issues critical stock PriceWatch Alerts for ABT, EBAY, LUV, MS, and RIOT. See the suitability of trading on these stocks today....
Apr 18, 2018 07:45 am ET
Abbott Reports First-Quarter 2018 Results
ABBOTT PARK, Ill., April 18, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2018....
Apr 17, 2018 09:30 am ET
Abbott's New Ensure® Max Protein Helps Americans Go for Their #HealthGoals
ABBOTT PARK, Ill., April 17, 2018 /PRNewswire/ -- Let's be honest – as adults, our busy schedules can get in the way of our own self-care, and that includes getting the right nutrition. The numbers back this up: more than 1 in 3 adults over 50 still aren't getting the protein they need daily, according to new National Health and Nutrition Examination Survey (NHANES) data from researchers at Abbott (NYSE: ABT) and the Ohio State University. That's why Abbott is introducing Ensure® Max Protein – a 150-calorie nutrition drink with 30 grams of high-quality protein and 1 gram of sugar – to help a...
Apr 17, 2018 07:40 am ET
Investor Expectations to Drive Momentum within Bank of America, Abbott Laboratories, Analog Devices, Mohawk Industries, Maxwell Technologies, and Oracle — Discovering Underlying Factors of Influence
NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Bank of America Corporation (NYSE:BAC), Abbott...
Apr 11, 2018 09:00 am ET
Abbott Initiates Groundbreaking Study to Assess Superiority of High-Resolution Imaging Versus Standard-of-Care Angiography in Treating Coronary Artery Disease
ABBOTT PARK, Ill., April 11, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the initiation of a clinical trial evaluating long-term outcomes of patients who undergo stent implantation guided by high-resolution light-based imaging technology—called optical coherence tomography (OCT)—compared to a common X-ray-guided technique called angiography. The trial (ILUMIEN IV) is the first large-scale randomized global study using Abbott's OCT imaging in patients with high-risk, complex coronary artery disease. Patients in the study will be randomized to either OCT-guided or traditional angio...
Mar 29, 2018 09:00 am ET
Abbott Initiates Trial to Evaluate Improved Survival And Outcomes with the CardioMEMS Monitor
ABBOTT PARK, Ill., March 29, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS™ HF System. The GUIDE-HF trial will study whether the CardioMEMS device can improve survival and quality of life for people living with New York Heart Association (NYHA) Class II – IV heart failure. The CardioMEMS HF System has already been proven, when managed by a physician, to significantly reduce heart failure hospital admissions and improve the quality of life for people living with NYHA Class III heart failure. Doctors ...
Mar 21, 2018 09:00 am ET
Abbott Hosts Conference Call for First-Quarter Earnings
ABBOTT PARK, Ill., March 21, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2018 financial results on Wednesday, April 18, 2018, before the market opens.  ...
Mar 19, 2018 09:00 am ET
Abbott's MitraClip Therapy Receives National Reimbursement in Japan to Treat Patients with Mitral Regurgitation
ABBOTT PARK, Ill., March 19, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the Ministry of Health Labour and Welfare (MHLW) in Japan granted national reimbursement for the company's MitraClip therapy to treat people with mitral regurgitation, a serious, progressive heart disease in which the mitral valve does not close properly, allowing blood to flow backward into the heart....
Mar 11, 2018 10:59 am ET
New Long-Term Data Show Improved Survival and Lower Rates of Stroke and Pump Thrombosis for Abbott's HeartMate 3 Heart Pump
ORLANDO, Fla., March 11, 2018  /PRNewswire/ -- Abbott (NYSE: ABT) announced new late-breaking clinical trial data from the MOMENTUM 3 clinical study, the largest left ventricular assist device (LVAD) trial in the world to evaluate patients in need of both short-term and long-term support in a single study. The data were published online in The New England Journal of Medicine (NEJM) and presented during a late-breaking session at the American College of Cardiology's (ACC) 67th Annual Scientific Session....
Mar 06, 2018 05:07 pm ET
FDA Approves the World's Smallest Mechanical Heart Valve for Pediatric Patients with Heart Defects
ABBOTT PARK, Ill., March 6, 2018 /PRNewswire/ -- Abbott today announced the U.S. Food and Drug Administration (FDA) approved the Masters HP™ 15mm rotatable mechanical heart valve, the world's smallest mechanical heart valve, that will allow doctors to treat babies and toddlers in need of a mitral or aortic valve replacement. Until today, surgeons could only use a range of larger-sized valves to replace a pediatric heart valve that could not be repaired, and larger valves are often not suitable given the smaller size of children's hearts. This dime-sized new valve is the first and only pediat...
Mar 01, 2018 08:00 am ET
Abbott to Present at the Barclays Capital 2018 Global Healthcare Conference
ABBOTT PARK, Ill., March 1, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will participate in the Barclays Capital Global Healthcare Conference on Wednesday, March 14, 2018. Brian Yoor, executive vice president, finance and chief financial officer, will present at 2:20 p.m. Central time....
Feb 27, 2018 08:00 am ET
Abbott and Surmodics Announce Agreement for Next-Generation Drug-Coated Balloon
ABBOTT PARK, Ill. and EDEN PRAIRIE, Minn., Feb. 27, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) and Surmodics (NASDAQ: SRDX) today announced that the companies have entered into an agreement whereby Abbott will have exclusive worldwide commercialization rights for Surmodics' SurVeil® drug-coated balloon to treat the superficial femoral artery, which is currently being evaluated in a U.S. pivotal clinical trial. Separately, Abbott also received options to negotiate agreements for Surmodics' below-the-knee and arteriovenous (AV) fistula drug-coated balloon products, which are currently in pre-clin...
Feb 16, 2018 10:20 am ET
Abbott Declares 377th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., Feb. 16, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 28 cents per share....
Feb 07, 2018 08:00 am ET
Abbott's App for FreeStyle® Libre System Now Available in Europe for Both iPhone™ and Android™
ABBOTT PARK, Ill., Feb. 7, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the FreeStyle LibreLink app is now available in Europe for use with compatible smartphones2 (both iPhone and Android). People with diabetes living in Europe and using the FreeStyle® Libre system3 are now able to access glucose data directly from their smartphones, eliminating the need to carry the separate FreeStyle Libre reader4 (a handheld device used to scan the FreeStyle Libre sensor to get a glucose result). Since 2015 the app offering for the FreeStyle Libre system was only available for Android users bu...
Feb 01, 2018 08:00 am ET
Market Trends Toward New Normal in Alexander's, Atrion, FS, Gilead Sciences, Abbott Laboratories, and Johnson & Johnson — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alexander's, Inc. (NYSE:ALX), Atrion Corporation (NASDAQ:ATRI),...
Jan 24, 2018 06:45 am ET
Abbott Reports Fourth-Quarter 2017 Results
ABBOTT PARK, Ill., Jan. 24, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2017....
Jan 04, 2018 08:00 am ET
Abbott's Revolutionary Continuous Glucose Monitoring System, FreeStyle® Libre, Now Available To Medicare Patients
ABBOTT PARK, Ill., Jan. 4, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the FreeStyle® Libre System, the company's revolutionary new continuous glucose monitoring (CGM) system, is now available to Medicare patients, having met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS). Coverage includes all Medicare patients with diabetes who use insulin and who meet the eligibility criteria2....
Jan 03, 2018 08:00 am ET
New FDA MR-Conditional Labeling Approvals Further Expand Abbott's Portfolio of MRI-Ready Devices
ABBOTT PARK, Ill., Jan. 3, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for the Quadra Assura MP™ Cardiac Resynchronization Therapy Defibrillator (CRT-D) and Fortify Assura™ Implantable Cardioverter Defibrillator (ICD), two of the company's most widely-used high voltage medical devices. The approvals follow recent MR-conditional labeling approvals for the Assurity MRI™ pacemaker, Ellipse™ ICD and associated MRI-compatible leads, and further expand Abbott's portfolio of MRI-ready devic...
Jan 02, 2018 08:00 am ET
Abbott Launches Alinity™ h-series Integrated Hematology System, Combining Speed, Accuracy and Seamless Integration
ABBOTT PARK, Ill., Jan. 2, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced CE Mark for its Alinity h-series integrated system for hematology testing, joining the Alinity hq standalone hematology analyzer, which obtained CE Mark earlier this year....
Dec 18, 2017 08:00 am ET
Abbott Hosts Conference Call for Fourth-Quarter Earnings
ABBOTT PARK, Ill., Dec. 18, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2017 financial results on Wednesday, Jan. 24, 2018, before the market opens.  ...
Dec 15, 2017 09:17 am ET
Abbott Raising Quarterly Dividend for 46th Straight Year
ABBOTT PARK, Ill., Dec. 15, 2017 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend to 28 cents per share from 26.5 cents per share....
Nov 28, 2017 07:35 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Juno Therapeutics, Abbott Laboratories, Freeport-McMoran, HP, The Trade Desk, and Platform Specialty Products — New Research Emphasi
NEW YORK, Nov. 28, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Juno Therapeutics, Inc. (NASDAQ:JUNO), Abbott Laboratories...
Nov 06, 2017 08:00 am ET
Abbott's MitraClip Approved as First Transcatheter Mitral Valve Repair Device in Japan
ABBOTT PARK, Ill., Nov. 6, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the company's MitraClip device for treatment of people with mitral regurgitation (MR), a serious, progressive heart disease in which the mitral valve does not close properly, allowing blood to flow backward into the heart....
Oct 31, 2017 10:00 am ET
Abbott Announces FDA Clearance for its Alinity™ ci-series Next-generation Diagnostic Systems
ABBOTT PARK, Ill., Oct. 31, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) has secured U.S. Food and Drug Administration (FDA) 510(k) clearance for its Alinity™ ci-series instruments for clinical chemistry and immunoassay diagnostics. These innovative testing solutions were designed to help the lab more effectively address modern industry challenges, including aging populations, growing management of chronic diseases and increased access to care, which are driving increases in testing volume. ...
Oct 30, 2017 02:20 pm ET
Analysis of Landmark Study Showed Patients Treated for Left-Main Coronary Artery Disease with XIENCE Stent Felt Better Faster and Had Similar Long-Term Outcomes to Open-Heart Surgery
DENVER, Oct. 30, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that patients who underwent minimally-invasive implantation with a XIENCE coronary stent for left-main coronary artery disease had the same long-lasting health outcomes at three years but felt better more quickly than patients who underwent open-heart surgery.  ...
Oct 30, 2017 08:00 am ET
Abbott Introduces Next Generation of Most Widely Used Heart Stent for People with Coronary Artery Disease in Europe[1]
ABBOTT PARK, Ill., Oct. 30, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it received CE Mark for XIENCE Sierra, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent system. CE Mark allows sale of the device in the European Union and other countries that recognize CE Mark. Advances in this generation of XIENCE — which is known for its exceptional safety — include new features that make it easier for cardiologists to successfully complete complex procedures that now account for up to 70 percent of cases.2 ...
Oct 23, 2017 10:00 am ET
Abbott Launches the First and Only Smartphone Compatible Insertable Cardiac Monitor in the U.S.
ABBOTT PARK, Ill., Oct. 23, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) has secured U.S. Food and Drug Administration (FDA) clearance for the Confirm Rx™ Insertable Cardiac Monitor (ICM), the world's first and only smartphone compatible ICM designed to help physicians remotely identify cardiac arrhythmias. With FDA clearance Abbott can now provide U.S. patients a new way to monitor for abnormal heart rhythms while staying connected to their physician remotely and being able to engage in their health care....
Oct 19, 2017 03:59 pm ET
A Great Place to Do Great Things: Developing Game-Changing Technology at Abbott
ABBOTT PARK, Ill., Oct. 19, 2017 /PRNewswire/ -- Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world.  ...
Oct 18, 2017 08:45 am ET
Abbott Reports Third-Quarter 2017 Results
ABBOTT PARK, Ill., Oct. 18, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2017....
Oct 16, 2017 10:00 am ET
Patients Battling Complex Regional Pain Syndrome Find a Host of New Benefits in Abbott's Proclaim™ DRG System
ABBOTT PARK, Ill., Oct. 16, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. launch of the company's Proclaim™ DRG Neurostimulator System, a new device designed to deliver stimulation to the dorsal root ganglion (DRG) and alleviate pain in patients suffering from complex regional pain syndrome (CRPS) of the lower limbs. With the Proclaim DRG system, Abbott has added new, patient-centric benefits to a device capable of delivering the company's sustained and superior pain relief for patients battling CRPS....
Oct 04, 2017 09:00 am ET
Abbott Completes Cash Tender Offer for Series B Convertible Perpetual Preferred Stock of Alere Inc.
ABBOTT PARK, Ill., Oct. 4, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it has successfully completed its previously announced tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock (the "Preferred Stock") of Alere Inc. ("Alere") at a price (the "Offer Price") of $402.00 per share of Preferred Stock, plus accrued but unpaid dividends to, but not including, the settlement date of the tender offer, net to the seller thereof in cash, without interest thereon and subject to any withholding of taxes required by applicable law (th...
Oct 02, 2017 09:00 am ET
Abbott Announces Extension of Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc.
ABBOTT PARK, Ill., Oct. 2, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it is extending its previously announced tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock (the "Preferred Stock") of Alere Inc. ("Alere") at a price of $402.00 per share of Preferred Stock, plus accrued but unpaid dividends to, but not including, the settlement date of the tender offer, net to the seller thereof in cash, without interest thereon and subject to any withholding of taxes required by applicable law (the "Offer"). The Offer is being mad...
Sep 29, 2017 10:20 am ET
Abbott Acquisition of Alere Set to Close on Tuesday, October 3, 2017
ABBOTT PARK, Ill., Sept. 29, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it intends to close the acquisition of Alere, Inc., on Tuesday, Oct. 3, 2017. The announcement follows receipt of all regulatory clearances necessary for closing.  ...
Sep 27, 2017 06:42 pm ET
No More Routine Finger Sticks(1) for Americans with Diabetes: Abbott′s FreeStyle® Libre Approved in the U.S.
ABBOTT PARK, Ill., Sept. 27, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle® Libre Flash Glucose Monitoring System as a replacement1 for blood glucose monitoring (BGM) for adults with diabetes in the U.S. This revolutionary new glucose sensing technology eliminates the need for routine finger sticks1 and is the only personal continuous glucose monitor (CGM) that does not require finger stick calibration. Designed to be approachable, accessible and affordable for the 30 million people with diabetes in America...
Sep 22, 2017 09:00 am ET
Abbott Secures FDA Approval for MRI-Compatibility for the Company's Ellipse™ ICD
ABBOTT PARK, Ill., Sept. 22, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for one of Abbott's most widely-used implantable cardioverter defibrillators (ICD) and associated high voltage leads. The approval of MR-conditional labeling for the Ellipse™ ICD with the Tendril MRI pacing lead and Durata and Optisure high voltage leads adds another patient-centric benefit to the device and will help further improve access for patients suffering from abnormally fast heart rhythms who need an IC...
Sep 20, 2017 10:00 am ET
Abbott Hosts Conference Call for Third-Quarter Earnings
ABBOTT PARK, Ill., Sept. 20, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2017 financial results on Wednesday, Oct. 18, 2017, before the market opens.  ...
Sep 18, 2017 09:00 am ET
Abbott Announces Extension of Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc.
ABBOTT PARK, Ill., Sept. 18, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it is extending its previously announced tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock (the "Preferred Stock") of Alere Inc. ("Alere") at a price of $402.00 per share of Preferred Stock, plus accrued but unpaid dividends to, but not including, the settlement date of the tender offer, net to the seller thereof in cash, without interest thereon and subject to any withholding of taxes required by applicable law (the "Offer"). The Offer is being m...
Sep 14, 2017 01:28 pm ET
Abbott Declares 375th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., Sept. 14, 2017 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 26.5 cents per share....
Sep 13, 2017 08:00 am ET
FreeStyle® Libre Flash Glucose Monitoring Technology Gains Reimbursement Approval from the United Kingdom's National Health Service
ABBOTT PARK, Ill., Sept. 13, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the FreeStyle® Libre system is now available for reimbursement in the United Kingdom (UK). The National Health Service (NHS) Business Services Authority has approved the listing on the Drug Tariff for the FreeStyle Libre system for people with diabetes using insulin. This means that from Nov. 1, 2017 it will be available for reimbursementiii via the NHS across England and Wales, NHS Scotland, and the Health and Social Care in Northern Ireland. ...
Sep 07, 2017 12:49 pm ET
Abbott Named Industry Leader for Responsible and Sustainable Business for Five Consecutive Years on the Dow Jones Sustainability Index (DJSI)
ABBOTT PARK, Ill., Sept. 7, 2017 /PRNewswire/ -- For the fifth consecutive year, Abbott (NYSE: ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability and responsibility. As the Industry Group Leader in Health Care Equipment & Services, Abbott is the only U.S.-based company of the 24 recognized for leading their respective global industry groups....
Sep 01, 2017 09:00 am ET
Abbott Announces Extension of Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc.
ABBOTT PARK, Ill., Sept. 1, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it is extending its previously announced tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock (the "Preferred Stock") of Alere Inc. ("Alere") at a price of $402.00 per share of Preferred Stock, plus accrued but unpaid dividends to, but not including, the settlement date of the tender offer, net to the seller thereof in cash, without interest thereon and subject to any withholding of taxes required by applicable law (the "Offer"). The Offer is being ma...
Aug 31, 2017 10:00 am ET
Revolutionary Glucose Monitoring Technology FreeStyle® Libre Now Reimbursed Across Japan
ABBOTT PARK, Ill., Aug. 31, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the Ministry of Health Labour and Welfare (MHLW) in Japan has granted national reimbursement for the FreeStyle® Libre glucose monitoring system effective September 1, 2017. The revolutionary system will be widely available to the more than 1 million Japanese people ages six and above with diabetes, both Type 1 and Type 2, on insulin therapy. ...
Aug 30, 2017 12:55 pm ET
Abbott initiates ground-breaking U.S. pivotal study of AMPLATZER device to correct common congenital heart defect in newborns
ABBOTT PARK, Ill., Aug. 30, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified version of its AMPLATZER™ device designed to correct a common congenital heart defect that occurs in approximately 80,000 i,ii pre-term infants in the U.S. each year.   ...
Aug 29, 2017 04:02 pm ET
Abbott and the Abbott Fund Donate $1 Million to Support Hurricane Harvey Relief Efforts
ABBOTT PARK, Ill., Aug. 29, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) and its foundation, the Abbott Fund, are providing $1 million in grants and healthcare and nutrition products to help deliver immediate relief following Hurricane Harvey and the devastating flooding affecting Texas and Louisiana. ...
Aug 28, 2017 10:00 am ET
Abbott Introduces HeartMate 3 Left Ventricular Assist System - the Latest Milestone In Therapy For Advanced Heart Failure Patients
ABBOTT PARK, Ill., Aug. 28, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev™ HeartMate 3™ Left Ventricular Assist System (also known as an LVAD). The HeartMate 3 system provides a new option for physicians managing advanced heart failure patients in need of short-term hemodynamic support (bridge-to-transplant or bridge to myocardial recovery). The system also provides patients living with their device new benefits that embody the evolution of left ventricular assist device (LVAD) therapy, such as imp...
Aug 15, 2017 09:00 am ET
North West London Pathology and Abbott Partner for Diagnostics Products and Services, including Alinity™, in Three NHS Trusts
LONDON, Aug. 15, 2017 /PRNewswire/ -- North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust, and Abbott (NYSE: ABT) announced today that they signed a $252 million managed equipment services contract for the supply of all analytical equipment and consumables, including Abbott's Alinity™ ci and Alinity h series diagnostics instruments as well as their professional services and informatics solutions known as AlinIQ....
Aug 14, 2017 09:00 am ET
Abbott Announces Extension of Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc.
ABBOTT PARK, Ill., Aug. 14, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it is extending its previously announced tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock (the "Preferred Stock") of Alere Inc. ("Alere") at a price of $402.00 per share of Preferred Stock, plus accrued but unpaid dividends to, but not including, the settlement date of the tender offer, net to the seller thereof in cash, without interest thereon and subject to any withholding of taxes required by applicable law (the "Offer"). The Offer is being ma...
Aug 10, 2017 10:00 am ET
The Cost of Malnutrition: Study Shows Nutrition Program Could Save Hospitals up to $3,800 per Patient
ABBOTT PARK, Ill. and DOWNERS GROVE, Ill., Aug. 10, 2017 /PRNewswire/ -- Making sure people stay nourished in the hospital has shown to help patients recover, and real-world evidence confirms its cost benefits too. The research, published in American Health & Drug Benefits journal and supported by Abbott (NYSE: ABT), found that when Advocate Health Care implemented a nutrition care program at four of its Chicago area hospitals, it showed more than $4.8 million in cost savings due to shorter hospital stays and lower readmission rates.3...
Jul 20, 2017 08:45 am ET
Abbott Reports Second-Quarter 2017 Results
ABBOTT PARK, Ill., July 20, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2017....
Jul 17, 2017 09:17 am ET
Abbott Commences Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc.
ABBOTT PARK, Ill., July 17, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock (the "Preferred Stock") of Alere Inc. ("Alere") at a price of $402.00 per share of Preferred Stock, plus accrued but unpaid dividends to, but not including, the settlement date of the tender offer, net to the seller thereof in cash, without interest thereon and subject to any withholding of taxes required by applicable law (the "Offer"). The Offer is being made pursuant to an Offe...
Jul 13, 2017 08:30 am ET
Abbott and Bigfoot Biomedical Announce Collaboration to Develop Breakthrough Diabetes Technologies
ABBOTT PARK, Ill. and MILPITAS, Calif., July 13, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) and Bigfoot Biomedical today announced that the companies have entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott's FreeStyle® Libre glucose sensing technologyi with Bigfoot's insulin delivery solutions in the United States....
Jun 29, 2017 02:32 pm ET
Abbott Secures Health Canada License for FreeStyle® Libre System for People with Diabetes
ABBOTT PARK, Ill., June 29, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the Health Canada license of its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for Canadian adults with diabetes. The first-of-its-kind system eliminates the need for routine finger sticks,1 requires no finger stick calibration, and reads glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days.  ...
Jun 21, 2017 10:00 am ET
Abbott Hosts Conference Call for Second-Quarter Earnings
ABBOTT PARK, Ill., June 21, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2017 financial results on Thursday, July 20, 2017, before the market opens.  ...
Jun 09, 2017 11:15 am ET
Abbott Declares 374th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., June 9, 2017 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 26.5 cents per share....
May 09, 2017 10:00 am ET
Abbott Announces CE Mark for TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™
ABBOTT PARK, Ill., May 9, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced CE Mark of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, developed to make it easier for physicians to more effectively treat atrial fibrillation (AF), a condition in which the upper chambers of the heart beat too fast. When integrated with Abbott's EnSite Precision™ cardiac mapping system, physicians are able to utilize dual impedance and magnetic technologies to help more precisely model the heart. This integrated system also helps physicians determine where to apply optimal contact force (...
May 08, 2017 10:00 am ET
Abbott Announces CE Mark and First Use of the World's First Smartphone Compatible Insertable Cardiac Monitor
ABBOTT PARK, Ill., May 8, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm Rx™ Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmias, including atrial fibrillation (AF), to help guide therapy. Since CE Mark approval, adoption of the device has been strong and implants have occurred in 10 countries across Europe. The Confirm Rx ICM is designed to continuously monitor a patient's heart rhythm and proactively transmit information via the myMerlin™ mo...
May 08, 2017 07:00 am ET
Abbott Announces National Reimbursement for FreeStyle® Libre in France, Providing Access to Revolutionary Technology for People with Diabetes
PARIS, May 8, 2017 /PRNewswire/ -- Abbott today announced that the French Health Ministry has granted national reimbursement across France for FreeStyle® Libre—Abbott's revolutionary glucose monitoring technology that removes the need for routine finger sticks1 for people with diabetes. This reimbursement decision will mean access to the FreeStyle Libre system for hundreds of thousands of people from age four3 across France with both Type 1 and Type 2 diabetes who use insulin multiple times per day. ...
Apr 26, 2017 09:00 am ET
Abbott Introduces Science-Based Nutrition Drinks to Help Patients Have a Better Recovery from Surgery
ABBOTT PARK, Ill., April 26, 2017 /PRNewswire/ -- More than 48 million surgeries happen in the U.S. each year,1 and for many of those patients, food is off the table in the hours prior to their procedure. According to a new survey of 1,015 Americans, supported by Abbott, a majority (79 percent) of the respondents who had undergone surgery were instructed by a doctor not to eat or drink before their surgery.2 Yet, surgical guidelines from organizations including the American College of Surgeons and the latest research recommend that certain nutrition should be consumed before and after surger...
Apr 19, 2017 08:45 am ET
Abbott Reports First-Quarter 2017 Results
ABBOTT PARK, Ill., April 19, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2017....
Apr 14, 2017 07:00 am ET
Abbott and Alere Amend Terms of Merger Agreement
ABBOTT PARK, Ill. and WALTHAM, Mass., April 14, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) and Alere Inc. (NYSE: ALR) announced today that the companies have agreed to amend the existing terms of their agreement for Abbott's acquisition of Alere....
Mar 22, 2017 10:00 am ET
Abbott Hosts Conference Call for First-Quarter Earnings
ABBOTT PARK, Ill., March 22, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2017 financial results on Wednesday, April 19, 2017, before the market opens.  ...
Mar 19, 2017 03:00 pm ET
Late-Breaking Data Shows the CardioMEMS HF System is Effective in Reducing Heart Failure Hospitalizations and Cost of Care
WASHINGTON, March 19, 2017 /PRNewswire/ -- New late-breaking featured clinical research presented today adds strong clinical support for Abbott's CardioMEMS™ HF System as an effective real-world approach to reduce heart failure hospitalizations and combat the rising cost of heart failure. The CardioMEMS HF System is the first and only U.S. Food and Drug Administration-approved monitor that, when used by physicians to manage heart failure, has been shown to significantly reduce heart failure hospital admissions and improve the quality of life in patients with heart failure (NYHA Class III). T...
Mar 18, 2017 01:30 pm ET
Late-Breaking Data on Abbott's MitraClip® System Show Continued Benefit for People with Mitral Regurgitation, Most Common Heart Valve Disease
WASHINGTON, March 18, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced favorable one-year outcomes from the largest study of real-world experience for the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the United States. MitraClip treats people with degenerative mitral regurgitation (DMR, also known as leaky heart valve), a serious condition involving a dysfunction of the heart's mitral valve, which regulates blood flow into the heart's main pumping chamber.  ...
Mar 08, 2017 04:15 pm ET
Abbott to Present at Barclays Capital 2017 Global Healthcare Conference
ABBOTT PARK, Ill., March 8, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the Barclays Capital Global Healthcare Conference on Thursday, March 16, 2017. Brian Yoor, executive vice president, finance and chief financial officer, will present at 9:15 a.m. Central time. ...
Mar 08, 2017 09:00 am ET
New Study Results May Lead to a New Standard of Care for In Vitro Fertilization Treatment
ABBOTT PARK, Ill., March 8, 2017 /PRNewswire/ -- New study results published in Human Reproduction could pave the way for an additional treatment option for the estimated 1.5 million women worldwide who undergo in vitro fertilization (IVF) treatment each year1, 2. In the Lotus I study, which involved more than 1,000 women across 38 international sites, oral dydrogesterone had similar efficacy and tolerability to micronized vaginal progesterone (MVP), which is the current standard of care globally to prepare the uterus lining for pregnancy3.  ...
Mar 07, 2017 09:00 am ET
Abbott Announces Results of Early Tenders and Consents in Exchange Offers and Execution of Supplemental Indenture
ABBOTT PARK, Ill., March 7, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that, as of 5:00 p.m. New York City time, on March 6, 2017, the aggregate principal amounts of each series of notes listed in the table below issued by St. Jude Medical, LLC (successor to St. Jude Medical, Inc. - STJ), had been validly tendered and not validly withdrawn. Abbott is making this announcement in connection with its previously announced offers to exchange all validly tendered and accepted notes of each such series for new notes to be issued by Abbott, and the related solicitation of consents to am...
Feb 21, 2017 08:55 am ET
Abbott Commences Exchange Offers and Consent Solicitations for St. Jude Medical, LLC Notes
ABBOTT PARK, Ill., Feb. 21, 2017 /PRNewswire/ -- Abbott (NYSE:ABT) announced today that it has commenced offers to exchange all validly tendered and accepted notes of the following series issued by St. Jude Medical, LLC (successor to St. Jude Medical, Inc. - STJ) for notes to be issued by Abbott as described in, and for the consideration summarized in, the table below. A registration statement on Form S-4 relating to the issuance of the Abbott notes was filed with the Securities and Exchange Commission on Feb. 21, 2017, but has not yet been declared effective.  ...
Feb 17, 2017 11:25 am ET
Abbott Declares 373rd Consecutive Quarterly Dividend
ABBOTT PARK, Ill., Feb. 17, 2017 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 26.5 cents per share....
Feb 15, 2017 08:30 am ET
Real-World Data from Abbott's FreeStyle® Libre Show Association Between Higher Frequency of Glucose Monitoring and Improved Glucose Control for People with Diabetes
PARIS, Feb. 15, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the results of real-world use data[1] showing that people who scan more frequently using Abbott′s FreeStyle® Libre system spend less time in hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) while having improved average glucose levels. According to the data, more than 50,000 people with diabetes using the FreeStyle Libre system checked their glucose levels an average of 16 times per day—which is three times more than the minimum recommended U.S.[2] and European[3] guidelines for testing with the traditi...
Feb 02, 2017 08:00 am ET
U.S. FDA Grants Abbott the First Commercial Authorization for a Molecular Test to Detect Zika Virus Using Whole Blood
ABBOTT PARK, Ill., Feb. 2, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has authorized its molecular test, the Abbott RealTime ZIKA test, to detect Zika virus in whole blood (when collected alongside a patient-matched serum or plasma sample) for emergency use. This is the first molecular test made by a commercial manufacturer authorized to detect Zika in whole blood samples, which is significant since recent research suggests Zika virus can be detected in whole blood for a longer period of time (up to two months) and at higher level...
Feb 01, 2017 08:00 am ET
Abbott Announces U.S. Approval for its Assurity MRI™ Pacemaker, the World's Smallest, Longest-Lasting Wireless MRI-Compatible Pacemaker
ABBOTT PARK, Ill., Feb. 1, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for both the Assurity MRI™ pacemaker and the Tendril™ MRI pacing lead. Patients implanted with these low-voltage devices will have the ability to undergo full body magnetic resonance imaging (MRI) scans, if required. With the approval, the Assurity MRI pacemaker is now the world's smallest, longest-lasting wireless MRI-compatible pacemaker....
Jan 25, 2017 11:00 am ET
European Commission Clears Abbott Acquisition of Alere
WALTHAM, Mass., Jan. 25, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, announced that the European Commission has granted clearance for Abbott Laboratories (NYSE: ABT) to acquire Alere Inc....
Jan 25, 2017 07:45 am ET
Abbott Reports Fourth-Quarter 2016 Results
ABBOTT PARK, Ill., Jan. 25, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2016....
Jan 20, 2017 06:00 pm ET
New Study Demonstrates Spinal Cord Stimulation Can Reduce or Stabilize Opioid Use Among Chronic Pain Patients
ABBOTT PARK, Ill., Jan. 20, 2017 /PRNewswire/ -- New research has found spinal cord stimulation (SCS) therapy can be key to reducing or stabilizing the use of opioids in patients battling chronic pain. In a new study, researchers examined opioid usage data from more than 5,400 patients both prior to and after receiving an SCS system implant. In an SCS system, an implanted device similar to a pacemaker delivers low levels of electrical energy to nerve fibers, interrupting pain signals as they travel to the brain to reduce the sensation of pain. Researchers have found that average daily opioid...
Jan 18, 2017 08:00 am ET
Abbott Announces European Launch of the Proclaim™ DRG Neurostimulation System for the Management of Chronic Neuropathic Pain
ABBOTT PARK, Ill., Jan. 18, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the European launch of the new Proclaim™ DRG Neurostimulation System, designed to deliver dorsal root ganglion (DRG) stimulation to patients suffering from chronic neuropathic pain. Through the Proclaim platform's Bluetooth® wireless technology and iOS™ software, the Proclaim DRG Neurostimulation System offers patients a more intuitive therapy experience, compared to current systems with traditional controllers that can be difficult to operate. This new system will improve the experience of how patients inter...
Jan 17, 2017 08:00 am ET
New Data Confirms Abbott's Dorsal Root Ganglion Stimulation Offers Greater Treatment Success over Traditional Spinal Cord Stimulation
ABBOTT PARK, Ill., Jan. 17, 2017 /PRNewswire/ -- New data published in the January edition of Pain has confirmed the superiority of Abbott's dorsal root ganglion (DRG) stimulation therapy over traditional spinal cord stimulation (SCS) for patients suffering from complex regional pain syndrome (CRPS). The data, which include both short-term and long-term data from the ACCURATE study, also suggested that DRG stimulation benefits patients' total mood and activity levels. Abbott is the only company in the world approved to offer DRG stimulation....
Jan 12, 2017 04:00 pm ET
Abbott Announces U.S. Launch and First Commercial Use of the New EnSite™ Precision Cardiac Mapping System
ABBOTT PARK, Ill., Jan. 12, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the U.S. launch and the first commercial uses of the new EnSite Precision™ cardiac mapping system and Advisor™ FL Circular Mapping Catheter, Sensor Enabled™ to map cardiac arrhythmias during ablation treatments. The first commercial use of the system after U.S. Food and Drug Administration clearance occurred at the Intermountain Heart Institute at Intermountain Medical Center in Salt Lake City during ablation procedures conducted by electrophysiologist John Day, M.D. ...
Jan 10, 2017 07:00 am ET
Abbott Announces CE Mark for its "Alinity s" Blood and Plasma Screening System
ABBOTT PARK, Ill., Jan. 10, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today its Alinity™ s System for blood and plasma screening received CE Mark and is now available in Europe and other countries that recognize CE Mark. The new testing solution is designed to screen blood and plasma faster and more efficiently within a smaller footprint than Abbott's current systems. In a testing specialty that can require extensive hands-on time, the additional automation and flexibility of the Alinity s System helps blood and plasma centers improve productivity and maintain the highest levels of a...
Jan 10, 2017 07:00 am ET
Abbott Announces CE Mark for its Alinity ci-series Diagnostic Systems
ABBOTT PARK, Ill., Jan. 10, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today its Alinity™ ci-series instruments for clinical chemistry and immunoassay diagnostics have obtained CE Mark and are now available in Europe and other countries that recognize CE Mark. These innovative testing solutions help labs run more tests in less time, reduce human error and increase testing productivity. ...
Jan 09, 2017 09:31 am ET
Abbott Laboratories, The Gap, Micron, Pfizer Inc., and Wells Fargo & Co. and more offer option-trading opportunities that offer returns of more than 19%
CHICAGO, Jan. 9, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABT, GPS, MU, PFE, and WFC....
Jan 04, 2017 04:30 pm ET
Abbott Completes the Acquisition of St. Jude Medical
ABBOTT PARK, Ill., Jan. 4, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has completed the acquisition of St. Jude Medical, Inc., establishing the company as a leader in the medical device arena. The transaction provides Abbott with expanded opportunities for future growth and is an important part of the company's ongoing effort to develop a strong, diverse portfolio of devices, diagnostics, nutritionals and branded generic pharmaceuticals.  ...
Jan 03, 2017 06:35 pm ET
IDEXX Laboratories Set to Join the S&P 500; Chemours to Join S&P MidCap 400; Shake Shack to Join S&P SmallCap 600
NEW YORK, Jan. 3, 2017 /PRNewswire/ -- S&P MidCap 400 constituent IDEXX Laboratories, Inc. (NASD: IDXX) will replace St. Jude Medical, Inc. (NYSE: STJ) in the S&P 500, S&P SmallCap 600 constituent The Chemours Company (NYSE: CC) will replace IDEXX in the S&P MidCap 400, and Shake Shack Inc. (NYSE: SHAK) will replace Chemours in the S&P SmallCap 600 after the close of trading on Wednesday, January 4. S&P 100 & 500 constituent Abbott Laboratories (NYSE: ABT) is acquiring St. Jude Medical in a deal expected to be completed on or about that date, pending final conditi...
Dec 30, 2016 12:30 pm ET
Abbott Acquisition of St. Jude Medical Set to Close on January 4, 2017
ABBOTT PARK, Ill., Dec. 30, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it intends to close the acquisition of St. Jude Medical, Inc., on Wednesday, Jan. 4, 2017. The announcement follows receipt of all regulatory clearances necessary for closing.  ...
Dec 21, 2016 09:00 am ET
Abbott Hosts Conference Call for Fourth-Quarter Earnings
ABBOTT PARK, Ill., Dec. 21, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2016 financial results on Wednesday, Jan. 25, 2017, before the market opens.  ...
Dec 20, 2016 11:58 am ET
Stock option reports for Abbott Laboratories, KeyCorp, Marathon Oil Corporation, Rice Energy and Exxon Mobil include trade ideas that offer returns of 20% or more!
CHICAGO, Dec. 20, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABT, KEY, MRO, RICE, and XOM....
Dec 19, 2016 09:00 am ET
Abbott to Present at J.P. Morgan Healthcare Conference
ABBOTT PARK, Ill., Dec. 19, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2017. Brian Yoor, senior vice president, finance and Chief Financial Officer, will present at the conference at 6 p.m. Central time....
Dec 09, 2016 10:25 am ET
Abbott Raising Quarterly Dividend for 45th Straight Year
ABBOTT PARK, Ill., Dec. 9, 2016 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend to 26.5 cents per share from 26 cents per share....
Dec 07, 2016 12:59 pm ET
Alere Issues Statement Regarding Abbott Lawsuit
WALTHAM, Mass., Dec. 7, 2016 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today issued the following statement in response to a lawsuit filed by Abbott Laboratories (NYSE: ABT) in the Delaware Court of Chancery to terminate Abbott's pending merger agreement with Alere: ...
Dec 07, 2016 11:14 am ET
Abbott Seeks to Terminate Alere Acquisition
ABBOTT PARK, Ill., Dec. 7, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) has filed a complaint to terminate its proposed acquisition of Alere based on the substantial loss in Alere's value following the merger agreement....
Dec 06, 2016 08:00 am ET
Study: Hospital Nutrition Program Shortens Patient Stays and Reduces Readmissions
DOWNERS GROVE, Ill. and ABBOTT PARK, Ill., Dec. 6, 2016 /PRNewswire/ -- While proper nutrition is vital to staying healthy, its importance becomes more critical for patients recovering in the hospital.  A new study by Advocate Health Care and Abbott (NYSE: ABT) found that optimizing nutrition care in the hospital could help reduce 30-day readmission rates by 27 percent and the average hospital stay by almost two days for malnourished patients. ...
Nov 30, 2016 07:00 am ET
Abbott Announces CE Mark for i-STAT Alinity, a Pioneering, Handheld Blood Testing Platform
ABBOTT PARK, Ill., Nov. 30, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) announced today its i-STAT® Alinity™ System, an innovative, handheld blood testing platform, received CE Mark and is now for sale in Europe and other countries that recognize CE Mark. The portable device can perform and analyze the largest menu of blood tests on a single device, ranging from blood chemistries to cardiac markers, using only two to three drops of a person's blood.1 Delivering results in two to 10 minutes, i-STAT Alinity equips healthcare professionals with the information they need to make fast and accurate me...
Nov 07, 2016 07:00 am ET
Abbott's Absorb™ Bioresorbable Stent Approved as the First Fully Dissolving Heart Stent in Japan
ABBOTT PARK, Ill., Nov. 7, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the company's Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people in Japan with coronary artery disease....
Oct 27, 2016 03:00 pm ET
A Great Place to Work, According to Science
ABBOTT PARK, Ill., Oct. 27, 2016 /PRNewswire/ -- Don't trust us, trust Science: Abbott is among the best science-based companies to work for in the world....
Oct 26, 2016 03:00 pm ET
New Study: Babies Fed Infant Formula with 2'-FL Human Milk Oligosaccharide+ Had Immune Response More Like Breastfed Babies
ABBOTT PARK, Ill., Oct. 26, 2016 /PRNewswire/ -- Good nutrition helps build the foundation for a child's ability to learn, grow and thrive. For babies, the best nutrition is breast milk – there's nothing in the world like it – in part due to special prebiotics called human milk oligosaccharides (HMOs). HMOs, found naturally in breast milk, feed good bacteria in the gut. Researchers believe they may be one of the main reasons breastfeeding provides immune health benefits. Now, a new study offers news about HMOs for parents who need or choose to use infant formula....
Oct 20, 2016 12:17 pm ET
People's Republic of China Clears Abbott Acquisition of Alere
WALTHAM, Mass., Oct. 20, 2016 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics announced that it has received notification from the Ministry of Commerce of the People's Republic of China (PRC) that after completing its review of the proposed acquisition the PRC has decided not to prohibit the acquisition of Alere Inc. by Abbott Laboratories (NYSE: ABT)....
Oct 19, 2016 10:31 am ET
Apple trade offers a 6.13% return in 58 days, or find similar option trades on MakeMyTrip Limited, Harley Davidson Inc., Walmart Stores Inc., and Abbott Laboratories
CHICAGO, Oct. 19, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, ABT, HOG, MMYT, and WMT....
Oct 19, 2016 08:45 am ET
Abbott Reports Third-Quarter 2016 Results
ABBOTT PARK, Ill., Oct. 19, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2016....
Oct 18, 2016 09:00 am ET
St. Jude Medical and Abbott to Sell Portion of Vascular Closure and Electrophysiology Businesses to Terumo Corporation
ABBOTT PARK, Ill. and ST. PAUL, Minn., Oct. 18, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) and St. Jude Medical, Inc. (NYSE: STJ) announced today an agreement in principle to sell certain products to Terumo Corporation. The transaction reflects a purchase price of approximately $1.12 billion and is subject to the successful completion of Abbott's acquisition of St. Jude Medical and antitrust regulatory approvals. Abbott, St. Jude Medical and Terumo are bound by the terms of an exclusivity agreement....
Oct 13, 2016 07:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT
NEW YORK, Oct. 13, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT) (ISIN: US0028241000). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Sep 28, 2016 10:00 am ET
Abbott Receives FDA Approval for the FreeStyle Libre Pro™ System, a Revolutionary Diabetes Sensing Technology for Healthcare Professionals to Use with Their Patients
ABBOTT PARK, Ill., Sept. 28, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's FreeStyle Libre Pro system, a revolutionary continuous glucose monitoring (CGM) system for healthcare professionals to use with their patients with diabetes. ...
Sep 21, 2016 03:00 pm ET
Malnutrition Adds $15.5 Billion Annually to Direct U.S. Medical Costs
ABBOTT PARK, Ill., Sept. 21, 2016 /PRNewswire/ -- Healthcare spending in the U.S. is higher than any other country,2 and a major contributor of that cost is treating chronic diseases. One barrier to better health for people living with a chronic disease is malnutrition, and new data shows that it is raising costs at the state level too. A study recently published in PLOS ONE, the world's first multidisciplinary open access journal, found that the U.S. spends upwards of $15.5 billion per year in direct medical costs on malnutrition associated with eight diseases – for individual states that c...
Sep 21, 2016 10:00 am ET
Abbott Hosts Conference Call for Third-Quarter Earnings
ABBOTT PARK, Ill., Sept. 21, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2016 financial results on Wednesday, Oct. 19, 2016, before the market opens.  ...
Sep 20, 2016 10:00 am ET
Fueling Performance with Fat: EAS® Launches First Ketogenic Meal Replacement For Athletes
ABBOTT PARK, Ill., Sept. 20, 2016 /PRNewswire/ -- While some endurance, strength and physique athletes try to minimize their intake of fat, others are embracing a high-fat, ketogenic nutrition plan. To help those athletes build stronger, leaner bodies and meet endurance goals, EAS Sports Nutrition is introducing a Myoplex Ketogenic shake. ...
Sep 16, 2016 04:00 pm ET
Abbott to Sell Abbott Medical Optics to Johnson & Johnson for $4.325 Billion
ABBOTT PARK, Ill., Sept. 16, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it will sell Abbott Medical Optics, its vision care business, to Johnson & Johnson for $4.325 billion in cash.  ...
Sep 15, 2016 10:00 am ET
Abbott Declares 371st Consecutive Quarterly Dividend
ABBOTT PARK, Ill., Sept. 15, 2016 /PRNewswire/ -- The board of directors of Abbott today declared a quarterly common dividend of 26 cents per share....
Sep 08, 2016 02:10 pm ET
Abbott Named Industry Leader for Responsible and Sustainable Business for Four Consecutive Years on the Dow Jones Sustainability Index (DJSI)
ABBOTT PARK, Ill., Sept. 8, 2016 /PRNewswire/ -- For the fourth consecutive year, Abbott (NYSE: ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability and responsibility. As the Industry Group Leader in Health Care Equipment & Services, Abbott is one of only two U.S.-based companies of the 24 recognized for leading their respective global industry groups. ...
Aug 24, 2016 10:00 am ET
Abbott to Present at Wells Fargo Healthcare Conference
ABBOTT PARK, Ill., Aug. 24, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the Wells Fargo 2016 Healthcare Conference on Wednesday, Sept. 7, 2016. Brian Yoor, senior vice president, finance and chief financial officer, will present at 7:45 a.m. Central time. ...
Aug 02, 2016 11:00 am ET
Abbott Unveils Alinity™, its Unified Family of Innovative Next-Generation Diagnostics Systems
ABBOTT PARK, Ill., Aug. 2, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the introduction of Alinity™, its harmonized family of next-generation systems across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics. Each Alinity platform will include a number of features to help institutions, clinicians and laboratorians better navigate through a pressure-packed health care environment....
Jul 29, 2016 10:31 am ET
Bank of America trade offers a 9% return in 204 days, or find similar option trades on Ariad Pharmaceuticals, US Steel, CyberArk Software, and Abbott Laboratories
CHICAGO, July 29, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABT, ARIA, BAC, CYBR, and X....
Jul 20, 2016 08:45 am ET
Abbott Reports Second-Quarter 2016 Results
ABBOTT PARK, Ill., July 20, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2016....
Jul 15, 2016 01:49 pm ET
FDA Approves the Tecnis Symfony® Intraocular Lenses, the First and Only Extended Depth of Focus Lenses for People with Cataracts
ABBOTT PARK, Ill., July 15, 2016 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved the Tecnis Symfony® Intraocular Lenses for the treatment of cataracts. The first in a new category of intraocular lenses (IOLs), the Tecnis Symfony lenses are the only lenses in the United States that provide a full range of continuous high-quality vision following cataract surgery, while also mitigating the effects of presbyopia by helping people focus on near objects. The FDA approval includes a version of the lens for people with astigmatism, the Tecnis Sym...
Jul 14, 2016 02:15 pm ET
Health Canada approves Abbott's Absorb™ bioresorbable stent, the first fully dissolving heart stent
 -- Revolutionary device made of naturally dissolving material, similar to dissolving sutures...
Jul 14, 2016 10:31 am ET
Learn how to target a 20% return on Gilead Sciences, or get option-trade ideas on Aetna, Exelixis, Priceline and Abbott Laboratories or any stock you choose
CHICAGO, July 14, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABT, AET, EXEL, GILD, and PCLN....
Jul 06, 2016 10:30 am ET
InvestorsObserver releases covered-call reports for Bank of America, Pfizer Inc., Abbott Laboratories, The Kroger Co and CVS Caremark
CHICAGO, July 6, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABT, BAC, CVS, KR, and PFE....
Jul 05, 2016 12:22 pm ET
FDA approves Abbott's Absorb™ bioresorbable stent, the only fully dissolving heart stent
ABBOTT PARK, Ill., July 5, 2016 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration has approved the company's Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States....
Jun 23, 2016 10:31 am ET
Covered Call reports for Apple, SolarCity, Skyworks Solutions, NVIDIA, and Abbott Laboratories include trade ideas that offer returns of 20% or more!
CHICAGO, June 23, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, ABT, NVDA, SCTY, and SWKS....
Jun 22, 2016 10:00 am ET
Abbott Hosts Conference Call for Second-Quarter Earnings
ABBOTT PARK, Ill., June 22, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2016 financial results on Wednesday, July 20, 2016, before the market opens.  ...
Jun 13, 2016 10:00 am ET
Abbott Announces Positive Results from Groundbreaking Study of FreeStyle® Libre System for People with Type 1 Diabetes
NEW ORLEANS, June 13, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the results of the IMPACT clinical trial, which demonstrated that the FreeStyle® Libre system met its primary endpoint of a reduction in time spent in hypoglycemia (low glucose levels, defined as <70 mg/dL1) for people with type 1 diabetes. People in the trial who used Abbott's FreeStyle Libre sensor and reader system spent 38 percent less time in hypoglycemia, as compared to people who managed their glucose with traditional self-monitoring of blood glucose (SMBG) systems (pricking a finger to draw a drop of blo...
Jun 10, 2016 12:05 pm ET
Abbott Declares 370th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., June 10, 2016 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 26 cents per share....
May 10, 2016 01:41 pm ET
New Curate™ Kids Combines Wholesome Ingredients and Kid-Friendly Flavors to Help Parents Win Snack-time
ABBOTT PARK, Ill., May 10, 2016 /PRNewswire/ -- Parents know that kids need good nutrition to be their healthiest and grow to their full potential but when you're constantly on the go, it can be hard to find wholesome snacking options that kids will actually eat. With the launch of Curate Kids – a new line of nutritious snack bars made with good-for-you ingredients in kid-approved flavors – parents don't need to compromise. This filling snack is the perfect choice to help give your kids the fuel they need to get through a car ride, sports practice, camping trip, playground adventure or any o...
May 09, 2016 09:00 am ET
A Clever Way to Add Nutrition to Your Toddler's Favorite Foods: Go & Grow by Similac® Food Mix-Ins™
ABBOTT PARK, Ill., May 9, 2016 /PRNewswire/ -- Eating a balanced, nutritious diet is the foundation for healthy growth, and ideally, every toddler would happily gobble up nutrient-rich foods like broccoli and sweet potatoes. But in reality, it can take a while for certain foods to appeal to kids. This is why Abbott is launching new Go & Grow by Similac® Food Mix-Ins™ (Mix-Ins), the first toddler product designed to mix into your toddler's favorite foods like yogurt, oatmeal and macaroni and cheese. ...
May 08, 2016 04:30 pm ET
Abbott Announces Positive Results from Pivotal Study of Tecnis® Symfony IOL for Cataract Surgery
NEW ORLEANS, May 8, 2016 /PRNewswire/ -- Today Abbott (NYSE: ABT) announced that its pivotal clinical trial of the company's Tecnis® Symfony 1-Piece Acrylic Intraocular Lens (IOL) met its primary endpoint of improved intermediate vision.  Data from this study showed that people who received the Tecnis Symfony lens achieved significantly improved intermediate, as well as near, vision compared to those who received a monofocal IOL.  The data were presented today at the American Society of Cataract and Refractive Surgery (ASCRS) in New Orleans by Jason Jones, M.D., Jones Eye Clinic, Sioux City,...
May 04, 2016 05:00 pm ET
Abbott to Present at Deutsche Bank Health Care Conference
ABBOTT PARK, Ill., May 4, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the Deutsche Bank 41st Annual Health Care Conference on Thursday, May 5, 2016. Tom Freyman, executive vice president, finance and administration, and Brian Yoor, senior vice president, finance and chief financial officer, will present at 7 a.m. Central time. ...
May 04, 2016 10:00 am ET
America's Health Check-up: AARP and Abbott Survey Finds Half of Adults 50-Plus Wish They Had More Strength and Energy to Enjoy Daily Activities
ABBOTT PARK, Ill. and WASHINGTON, May 4, 2016 /PRNewswire/ -- While Americans are redefining what it means to age well and stay healthy, many adults 50 and over are still feeling the effects of aging. AARP and Abbott surveyed 1,480 Americans aged 50 years and older and found that while a majority see themselves in good health, one in two reported that they wished they had more strength or energy to participate in the activities they enjoy.1 ...